Y.S.H. (3705) reported revenue of NT$749.4 million for Oct 2026, +4.4% year on year and +13.7% from the previous month. Revenue for Jan–Oct 2026 was NT$6.53 billion (-5.8% year on year).
Year-on-year revenue growth: 4 months in a row. →
In Oct 2026, it ranked No. 8 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$749.4 million | +4.4% | +13.7% |
| Sep 2026 | NT$659.2 million | +8.7% | +4.2% |
| Aug 2026 | NT$632.9 million | +4.6% | -12.0% |
| Jul 2026 | NT$719.5 million | +2.7% | +24.5% |
| Jun 2026 | NT$577.9 million | -22.0% | -12.2% |
| May 2026 | NT$658 million | -3.2% | -5.2% |
| Apr 2026 | NT$693.9 million | -1.5% | +11.9% |
| Mar 2026 | NT$620.2 million | -23.7% | +18.5% |
| Feb 2026 | NT$523.5 million | -16.7% | -24.9% |
| Jan 2026 | NT$697.1 million | -5.6% | -3.4% |
| Dec 2025 | NT$722 million | -0.6% | +1.2% |
| Nov 2025 | NT$713.7 million | +2.9% | -0.5% |
| Oct 2025 | NT$717.7 million | -3.6% | +18.4% |
| Sep 2025 | NT$606.2 million | -1.0% | +0.2% |
| Aug 2025 | NT$605.1 million | -19.1% | -13.6% |
| Jul 2025 | NT$700.4 million | -5.4% | -5.4% |
| Jun 2025 | NT$740.7 million | +17.9% | +9.0% |
| May 2025 | NT$679.7 million | +1.2% | -3.5% |
| Apr 2025 | NT$704.7 million | +3.7% | -13.3% |
| Mar 2025 | NT$813 million | +51.8% | +29.4% |
| Feb 2025 | NT$628.1 million | +18.0% | -14.9% |
| Jan 2025 | NT$738.3 million | +1.3% | +1.6% |
| Dec 2024 | NT$726.3 million | +14.6% | +4.7% |
| Nov 2024 | NT$693.5 million | +0.1% | -6.9% |
| Oct 2024 | NT$744.6 million | +20.5% | +21.6% |
Jan–Oct 2026 cumulative: NT$6.53 billion (-5.8% YoY)
Other Biotech & Medical companies
Compare with peers: Y.S.H. vs PEC / Y.S.H. vs Lotus Pharm / Y.S.H. vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| GKB | NT$748.3 million | -30.8% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16